Video

Improving Treatment Requires Collaboration and Transparency

For physicians to make better treatment decisions, they need real-time, relevant information, states Andrew Pecora, MD. Claims data have limited use, since it is extremely difficult to determine clinical subsets, adds Michael Kolodziej, MD. To help improve decision-making, analytical tools built on robust data are needed.

In order to accomplish this, there first needs to be collaboration and transparency regarding the clinical subsets and cost structure. When a change is made to the system, there needs to be a way to measure the impact of that change, Kolodziej adds.

Transparency and collaboration are critical, agrees Jeffrey C. Ward, MD. Using WellPoint’s Pathways project as an example, he suggests that it is important for oncologists to understand the successes and failures of the programs being implemented. Whereas oncologists have historically viewed the pharmaceutical industry as its partner in patient care, this has not been the case with payers.

Developing partnerships between practices and payers is a good way to test the validity of different models. Also, in order to learn and to make appropriate changes, the information needs to be shared.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.